Comparative Study Identifies Divergent Immune Mechanisms for Cancer Resistance in Long-Lived African Mole-Rats

Researchers reported that while both Damaraland and naked mole-rats exhibit absolute resistance to chemical carcinogenesis, they employ divergent immune, transcriptomic, and tissue-protective strategies to prevent tumor development.

A study published in Geroscience compared the cancer-resistance mechanisms of two closely related long-lived rodent species: the Damaraland mole-rat (DMR) and the naked mole-rat (NMR).

DMRs exposed to two different chemical carcinogens developed no tumors over a period of more than three years, demonstrating a cancer-resistant phenotype comparable to that of NMRs.

Upon carcinogen exposure, DMRs exhibited robust immune cell infiltration and upregulated genes associated with both T cell-mediated and innate immune responses, alongside immunosuppressive molecules to modulate inflammation.

In contrast, NMRs showed minimal immune cell infiltration and limited transcriptional changes, instead engaging the keratinization and p53-related stress pathways to achieve tissue protection with attenuated inflammation.

Both species demonstrated low expression of Toll-like receptor genes and a loss of necroptosis induction, which the researchers report may help mitigate cancer-promoting tissue inflammation.

The findings establish that extreme cancer resistance in closely related long-lived mammals can be mediated by highly divergent physiological mechanisms rather than a single conserved pathway.

DMRs offer a model of active, tightly regulated immune response to carcinogen challenge, while NMRs present a model of passive tissue-level tolerance and stress resistance, providing two distinct paradigms for oncology research.

The shared suppression of necroptosis and Toll-like receptor pathways suggests key inflammatory regulatory nodes that could guide human anti-inflammatory and cancer-preventative therapeutic concepts.

The identification of divergent evolutionary strategies for tumor resistance expands the preclinical target pipeline for novel oncological and anti-inflammatory mechanisms.

The study highlights the potential utility of targeting necroptosis suppression or modulating specific Toll-like receptor pathways to reduce tissue inflammation in human clinical applications.

Because these findings are restricted to comparative rodent biology, the commercial impact remains highly long-term, requiring translation into human-compatible therapeutic modalities.

Future studies evaluating whether suppressing necroptosis or modulating Toll-like receptor pathways can replicate similar cancer-resistant phenotypes in human cell lines or preclinical mammalian models.